Global Immunotherapy Market Outlook, Industry Analysis and Prospect 2018-2023
Summary - A new market study, Global Immunotherapy Market Research and Forecast, 2018-2023 ” has been featured on WiseGuyReports.
Immunotherapy is a way of
treatment that boosts the body’s natural defense to fight cancer and other
diseases. Immunotherapy has proven to be an effective way for the treatment of
cancer as it has better chances of successfully fighting cancer and protect
patients from the disease for a longer period.
Increasing demand for targeted therapies over
traditional therapies is augmenting the need for immunotherapy globally. Drugs
such as Thalidomide, Lenalidomide, and Pomalidomide, were the treatment options
available in the last few years. Introduction of immunomodulatory drugs, such
as monoclonal antibodies and HDCA inhibitors, designed to target receptors for
myeloma, is expected to initiate newer trends in the market. Cancer immunotherapies
is widely being adopted due to the
drawbacks associated with chemotherapy such as organ failure,
recurrence of cancer and other side effects. Increasing support by various
governments to develop cancer immunotherapies will benefit in the growth of
this market. After the approval of Blincyto (blinatumomab) by Amgen, a
bispecific antibody that targets B-cell lymphoblastic leukemia has fuelled the
development of monoclonal antibodies as effective immunotherapeutic options.
Increasing investments in R&D pertaining to the use of monoclonal bodies as
naked antigen-binding antibodies, conjugated monoclonal antibodies, and
bispecific antibodies have resulted in the discovery of new therapeutic options
for cancer treatment.
However, the high cost of this drugs and stringent regulatory
policies in some regions are restraining market growth. The market for
immunotherapy will show significant growth in near future owing to the
introduction of new immunotherapeutic options, such as immunomodulators and
CAR-T cell therapy that are in the pipeline and being evaluated for their
effectiveness in treating cancer. Additionally, increase in a number of
approvals for new immunotherapeutic drugs such as Opdivo, Keytruda, and
Tecentriq approved for lung tumors are augmenting the growth of the market and
are prescribed in cases of reoccurrence of tumor post-chemotherapy.
The immunotherapy market is
segmented on the basis of type, application, and end-user. On the basis of
type, the market is bifurcated into monoclonal antibodies, cancer vaccines,
autoimmune checkpoint inhibitors, interleukins and interferon (cytokinins),
Bacillus Calmette-Guerin (BCG), adoptive cell therapy and other non-specific
immunotherapies. Monoclonal antibodies are one of the significant markets owing
to the rising investments on R&D of monoclonal antibodies. Monoclonal
antibodies for cancer treatment have opened new opportunities for revenue
generation for companies that provide oncology therapeutics. Checkpoint
inhibitors are used as an initial treatment in patients suffering from an
advanced lung tumor. On the basis of end-user, the market is divided into
hospitals and clinics, diagnostic centers and others.
The global immunotherapy market is studied on
the basis of the geographical regions that are contributing significantly
towards the growth of the market. North America is dominating the market for
immunotherapy owing to the high penetration of the drugs in the market and
greater adoption of immunotherapy drugs due to the high prevalence of cancer.
Additionally, factors such as the high affordability of therapies due to the
presence of well-structured reimbursement plans are the factors for the
preferable market growth in this region. Europe is the second largest market
for immunotherapy drugs owing to the greater expenditure on healthcare and the
presence of pharmaceutical companies in the region. Asia-Pacific is the fastest
growing market for immunotherapy drugs due to the increasing adoption of newer
forms of therapy for cancer treatment.
The companies contributing
to the growth of global immunotherapy market are Advaxis, Inc., AbbVie, Inc.,
AstraZeneca PLC, Adaptimmune Therapeutics PLC, Aduro Biotech, Inc., Bristol
Myer Squibb and Company, Ziopharm Oncology Inc. and so on. In August 2017, US
regulators approved a drug made by Novartis and marketed as Kymriah, the first
cancer drug that uses a patient’s own cells to fight cancer. It is a super
expensive and is priced at $475,000. Kymriah is an intravenous treatment
patient to treat acute lymphocytic leukemia, the most common type of childhood
cancer in the US.
Research methodology
The market study of the global immunotherapy
market is incorporated by extensive primary and secondary research conducted by
the research team at OMR. Secondary research has been conducted to refine the
available data to break down the market in various segments, derive total
market size, market forecast, and growth rate. Different approaches have been
worked on to derive the market value and market growth rate. Our team collects
facts and data related to the market from different geography to provide a
better regional outlook. In the report, the country level analysis is provided
by analyzing various regional players, regional tax laws and policies, consumer
behavior, and macroeconomic factors. Numbers extracted from secondary research
have been authenticated by conducting proper primary research. It includes
tracking down key people from the industry and interviewing them to validate
the data. This enables our analyst to derive the closest possible figures
without any major deviations in the actual number. Our analysts try to contact
as many executives, managers, key opinion leaders, and industry experts.
Primary research brings the authenticity of our reports.
Secondary sources include
• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• An authentic database such as the Immunotherapy Foundation, American Cancer
Society and so on.
• Company websites and their product/ services catalog.
The report is intended for biotechnology and life science companies, research
institutes and government organizations for overall market analysis and
competitive analysis. The report provides an in-depth analysis of market size,
growth opportunity in the market and product types. The report will serve as a
source for 360-degree analysis of the market thoroughly integrating different
models delivering insights into the market for better business decisions.
THE REPORT COVERS
• Comprehensive research methodology of global immunotherapy market.
• This report also includes a detailed and extensive market overview with
analyst insights & key market trends.
• An exhaustive analysis of macro and micro factors influencing the market
guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the
global immunotherapy market.
• Insights about market determinants which are stimulating the global
immunotherapy market.
• Detailed and extensive market segments with regional distribution of
forecasted revenues.
• Broad profiles and recent developments of market players.
Companies Mentioned
1. Advaxis, Inc.
2. AbbVie, Inc.
3. AstraZeneca PLC
4. Adaptimmune Therapeutics PLC
5. Aduro Biotech, Inc.
6. Agenus, Inc.
7. Atara Biotherapeutics, Inc.
8. Bellicum Pharmaceuticals, Inc.
9. Bristol Myer Squibb, Co.
10. Bluebird Bio, Inc.
11. Celldex Therapeutics, Inc.
12. CytomX Therapeutics
13. Gilead Science Inc.
14. Incyte Corporation
15. Johnson & Johnson, Inc.
16. Juno Therapeutics, Inc.
17. Jounce Therapeutics, Inc.
18. Novartis International AG
19. Merck & Co., Inc.
20. Xencor, Inc.
21. MacroGenics, Inc.
22. ZIOPHARM Oncology Inc.
About Us:
Wise Guy
Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers
premium progressive statistical surveying, market research reports, analysis
& forecast data for industries and governments around the globe.
Contact Us:
NORAH
TRENT
Ph:
+162-825-80070
(US)
Ph: +44 203
500 2763 (UK)
Comments
Post a Comment